Of the 596 non-small cell lung cancer (NSCLC) patients, 384 with a determined epidermal growth factor receptor (EGFR) mutation status, including 186 (48.4%, 186/384) with any or combined mutations of EGFR exon 18 to 21 and 198 with wild-type (WT) EGFR, were eligible for the identification of brain metastases (BM).